,text,position,name,last,events,dateString,collapsed,checked
0,"<p>New funding applications are referred to one of Pharmac's Funding Application Advisors (FAAs), who'll review the application to ensure they have the relevant information to undertake a preliminary analysis.&nbsp; They may seek more information if required.</p>
<p><a class=""external-link"" href=""https://www.pharmac.govt.nz/medicines/how-medicines-are-funded/new-funding-applications/"" rel=""nofollow"">https://www.pharmac.govt.nz/medicines/how-medicines-are-funded/new-funding-applications/</a></p>",0,Application Received,False,"[{'Summary': {'s': 'This application was the result of an Specialist Advisory Committee recommendation', 'fs': 'This application was the result of an Specialist Advisory Committee recommendation', 'change': None}, 'Published_Recommendation': {'s': None, 'fs': None, 'change': None}, 'Published_Discussion': {'s': None, 'fs': None, 'change': None}, 'Published_Application': {'s': None, 'fs': None, 'change': None}, 'PTAC_Comments': {'s': None, 'fs': None, 'change': None}, 'Outcome': {'s': None, 'fs': None, 'change': None}, 'Links': {'s': None, 'fs': None, 'change': None}, 'Formatted_Date': {'s': 'Nov 2021', 'fs': 'Nov 2021', 'change': None}, 'Event_Description': {'s': 'Application received', 'fs': 'Application received', 'change': None}, 'e': {'attributes': {'type': 'Application_Event__c', 'url': '/services/data/v65.0/sobjects/Application_Event__c/a0POZ00000PTOjn2AH'}, 'Id': 'a0POZ00000PTOjn2AH', 'Event_Date__c': '2021-11-01', 'Event_Description__c': 'Application received', 'Stage__c': 'Application Received', 'Summary__c': 'This application was the result of an Specialist Advisory Committee recommendation', 'Formatted_Date__c': 'Nov 2021', 'Status_History__c': 'a132P000000DU23QAG'}, 'change': None}]",Nov 2021,False,True
1,"<p>Pharmac is identifying and gathering information required to get clinical advice.  The <a class=""external-link"" href=""https://pharmac.govt.nz/about/expert-advice/pharmacology-and-therapeutics-advisory-committee-ptac/"" rel=""nofollow"">Pharmacology and Therapeutics Advisory Committee (PTAC)</a>  meets quarterly. There are also around 20 expert <a class=""external-link"" href=""https://pharmac.govt.nz/about/expert-advice/specialist-advisory-committees/"" rel=""nofollow"">Specialist Advisory Committees (SACs)</a>, previously expert Subcommittees, which provide clinical evaluations in specialist areas. Specialist Advisory Committees meet as required to discuss issues referred to them by PTAC or Pharmac.</p>
<p style=""height: 20px"">&nbsp;</p>
<p>In November 2021, we introduced separate terms of reference for the SACs to make clear that these committees have different, but complementary, roles, expertise and perspectives to PTAC.</p>
<p style=""height: 15px"">&nbsp;</p>
<p>PTAC and SACs may make recommendations to Pharmac that differ from each other when looking at the same evidence. Pharmac considers the recommendations provided by all our clinical advisory committees when assessing applications.</p>
<p style=""height: 20px"">&nbsp;</p>
<p><a class=""external-link"" href=""https://pharmac.govt.nz/about/expert-advice/pharmacology-and-therapeutics-advisory-committee-ptac/ptac-terms-of-reference-july-2021/"" rel=""nofollow"">PTAC</a>  and <a class=""external-link"" href=""https://pharmac.govt.nz/about/expert-advice/specialist-advisory-committees/specialist-advisory-committee-terms-of-reference//"" rel=""nofollow"">Specialist Advisory Committees</a> records of the meeting will be published on this website in accordance with the Terms of Reference.</p>",1,Seeking Clinical Advice,False,"[{'Summary': {'s': None, 'fs': None, 'change': None}, 'Published_Recommendation': {'s': None, 'fs': None, 'change': None}, 'Published_Discussion': {'s': None, 'fs': None, 'change': None}, 'Published_Application': {'s': None, 'fs': None, 'change': None}, 'PTAC_Comments': {'s': None, 'fs': None, 'change': None}, 'Outcome': {'s': None, 'fs': None, 'change': None}, 'Links': {'s': None, 'fs': None, 'change': None}, 'Formatted_Date': {'s': 'Nov 2021', 'fs': 'Nov 2021', 'change': None}, 'Event_Description': {'s': 'Clinical advice required', 'fs': 'Clinical advice required', 'change': None}, 'e': {'attributes': {'type': 'Application_Event__c', 'url': '/services/data/v65.0/sobjects/Application_Event__c/a0POZ00000PTOjo2AH'}, 'Id': 'a0POZ00000PTOjo2AH', 'Event_Date__c': '2021-11-01', 'Event_Description__c': 'Clinical advice required', 'Stage__c': 'Seeking Clinical Advice', 'Formatted_Date__c': 'Nov 2021', 'Status_History__c': 'a132P000000DU28QAG'}, 'change': None}, {'Summary': {'s': None, 'fs': None, 'change': None}, 'Published_Recommendation': {'s': None, 'fs': None, 'change': None}, 'Published_Discussion': {'s': None, 'fs': None, 'change': None}, 'Published_Application': {'s': None, 'fs': None, 'change': None}, 'PTAC_Comments': {'s': None, 'fs': None, 'change': None}, 'Outcome': {'s': None, 'fs': None, 'change': None}, 'Links': {'s': None, 'fs': None, 'change': None}, 'Formatted_Date': {'s': 'Nov 2021', 'fs': 'Nov 2021', 'change': None}, 'Event_Description': {'s': 'Assigned to Reproductive and Sexual Health Subcommittee meeting to provide advice on Monday 1 November 2021', 'fs': 'Assigned to Reproductive and Sexual Health Subcommittee meeting to provide advice on Monday 1 November 2021', 'change': None}, 'e': {'attributes': {'type': 'Application_Event__c', 'url': '/services/data/v65.0/sobjects/Application_Event__c/a0POZ00000PTOjp2AH'}, 'Id': 'a0POZ00000PTOjp2AH', 'Event_Date__c': '2021-11-01', 'Event_Description__c': 'Assigned to Reproductive and Sexual Health Subcommittee meeting to provide advice on Monday 1 November 2021', 'Stage__c': 'Seeking Clinical Advice', 'Formatted_Date__c': 'Nov 2021', 'Status_History__c': 'a132P000000DU3EQAW'}, 'change': None}, {'Summary': {'s': None, 'fs': None, 'change': None}, 'Published_Recommendation': {'s': None, 'fs': None, 'change': None}, 'Published_Discussion': {'s': '<p>The Subcommittee noted that lidocaine with prilocaine cream is currently only funded in the community for children with a chronic medical condition requiring frequent injections or venepuncture. The Subcommittee noted that in June 2021, Pharmac consulted on declining funding applications to widen access to lidocaine with prilocaine cream in the community (to open list and for pain) following decline recommendations from PTAC.</p><p><br></p><p>The Subcommittee considered that there is currently an unmet health need for pain management during intrauterine device (IUD) insertion and that this unmet need could be somewhat met by the availability of lidocaine with prilocaine cream. </p><p><br></p><p>The Subcommittee noted the following evidence for lidocaine with prilocaine use during IUD insertion:</p><p><br></p><p class=""ql-indent-1"">A systematic review and network meta-analysis evaluating different pain lowering medications during intrauterine device insertion (<a href=""https://doi.org/10.1016/j.fertnstert.2018.11.012"" target=""_blank"">Samy et al. Fertil Steril. 2019;111</a>). </p><p class=""ql-indent-1""><br></p><p class=""ql-indent-1"">An expert opinion publication regarding the impact on pain of lidocaine in IUD insertion (<a href=""https://journals.lww.com/ebp/Citation/2021/01000/Does_topical_lidocaine_reduce_pain_more_than.31.aspx"" target=""_blank"">Lerman and Nunes. EBP. 2021;24:38-9</a>). </p><p class=""ql-indent-1""><br></p><p class=""ql-indent-1"">A randomised double-blind controlled trial of cervical lidocaine-prilocaine cream on pain perception during copper IUD insertion (<a href=""https://doi.org/10.1016/j.contraception.2016.10.011"" target=""_blank"">Abbas et al. Contracept Elsevier Inc. 2017;95:251–6</a>). </p><p><br></p><p>The Subcommittee noted the New Zealand Aotearoa’s guidance on contraception (<a href=""https://www.health.govt.nz/system/files/documents/publications/final_aotearoa_contraception_guidance.pdf"" target=""_blank"">Ministry of Health 2020</a>). This notes that the <a href=""https://www.fsrh.org/documents/ceuguidanceintrauterinecontraception/"" target=""_blank"">United Kingdom’s Faculty of Sexual and Reproductive Healthcare</a> does not recommend routinely using topical lidocaine, misoprostol, or nonsteroidal anti-inflammatory drugs to improve ease of insertion or reduce pain during the insertion of IUC. The Subcommittee also noted that New Zealand Family Planning similarly does not recommend the routine use of topical pain relief agents, with oral analgesia (paracetamol and/or ibuprofen) instead recommended to be taken prior to insertion.</p><p><br></p><p>The Subcommittee noted that currently lidocaine urethral syringes are available on Practitioners Supply Order (PSO) and can be used for cervical administration. \xa0A cervical or paracervical block is not commonly used in the community. Members noted that misoprostol may also be used, however considered that none of these treatments adequately meet the health need for pain management associated with IUD insertion in the community. </p><p><br></p><p>The Subcommittee noted that lidocaine with prilocaine should not be used routinely for IUD insertion and that likely uptake would be a significant minority of all IUD insertions. Members considered that it would most likely be used, and the most benefit gained, in situations where an individual is hesitant to receive an IUD due to fear and/or anxiety of associated pain, and those anticipated to experience difficulties during insertion. Members considered that 2 ml (one 5 g tube) of lidocaine with prilocaine cream would likely be required per procedure. </p><p><br></p><p>Members considered that there may be an element of placebo effect with lidocaine with prilocaine use during IUD insertion and that some benefit may also result from additional lubrication from the cream. However, noting that a barrier to IUD access is fear related to insertion, the Subcommittee considered that, on balance, the availability of an evidence-based treatment to reduce pain would improve equitable access to IUDs and further support uptake. The Subcommittee <b>recommended</b> that lidocaine with prilocaine cream be funded for intra-uterine device insertion, noting that availability of appropriate pain relief, with evidence of benefit, is likely to improve the acceptability of IUDs and positively impact equitable uptake in the community setting.\xa0</p>', 'fs': '<p>The Subcommittee noted that lidocaine with prilocaine cream is currently only funded in the community for children with a chronic medical condition requiring frequent injections or venepuncture. The Subcommittee noted that in June 2021, Pharmac consulted on declining funding applications to widen access to lidocaine with prilocaine cream in the community (to open list and for pain) following decline recommendations from PTAC.</p><p><br></p><p>The Subcommittee considered that there is currently an unmet health need for pain management during intrauterine device (IUD) insertion and that this unmet need could be somewhat met by the availability of lidocaine with prilocaine cream. </p><p><br></p><p>The Subcommittee noted the following evidence for lidocaine with prilocaine use during IUD insertion:</p><p><br></p><p class=""ql-indent-1"">A systematic review and network meta-analysis evaluating different pain lowering medications during intrauterine device insertion (<a href=""https://doi.org/10.1016/j.fertnstert.2018.11.012"" target=""_blank"">Samy et al. Fertil Steril. 2019;111</a>). </p><p class=""ql-indent-1""><br></p><p class=""ql-indent-1"">An expert opinion publication regarding the impact on pain of lidocaine in IUD insertion (<a href=""https://journals.lww.com/ebp/Citation/2021/01000/Does_topical_lidocaine_reduce_pain_more_than.31.aspx"" target=""_blank"">Lerman and Nunes. EBP. 2021;24:38-9</a>). </p><p class=""ql-indent-1""><br></p><p class=""ql-indent-1"">A randomised double-blind controlled trial of cervical lidocaine-prilocaine cream on pain perception during copper IUD insertion (<a href=""https://doi.org/10.1016/j.contraception.2016.10.011"" target=""_blank"">Abbas et al. Contracept Elsevier Inc. 2017;95:251–6</a>). </p><p><br></p><p>The Subcommittee noted the New Zealand Aotearoa’s guidance on contraception (<a href=""https://www.health.govt.nz/system/files/documents/publications/final_aotearoa_contraception_guidance.pdf"" target=""_blank"">Ministry of Health 2020</a>). This notes that the <a href=""https://www.fsrh.org/documents/ceuguidanceintrauterinecontraception/"" target=""_blank"">United Kingdom’s Faculty of Sexual and Reproductive Healthcare</a> does not recommend routinely using topical lidocaine, misoprostol, or nonsteroidal anti-inflammatory drugs to improve ease of insertion or reduce pain during the insertion of IUC. The Subcommittee also noted that New Zealand Family Planning similarly does not recommend the routine use of topical pain relief agents, with oral analgesia (paracetamol and/or ibuprofen) instead recommended to be taken prior to insertion.</p><p><br></p><p>The Subcommittee noted that currently lidocaine urethral syringes are available on Practitioners Supply Order (PSO) and can be used for cervical administration. \xa0A cervical or paracervical block is not commonly used in the community. Members noted that misoprostol may also be used, however considered that none of these treatments adequately meet the health need for pain management associated with IUD insertion in the community. </p><p><br></p><p>The Subcommittee noted that lidocaine with prilocaine should not be used routinely for IUD insertion and that likely uptake would be a significant minority of all IUD insertions. Members considered that it would most likely be used, and the most benefit gained, in situations where an individual is hesitant to receive an IUD due to fear and/or anxiety of associated pain, and those anticipated to experience difficulties during insertion. Members considered that 2 ml (one 5 g tube) of lidocaine with prilocaine cream would likely be required per procedure. </p><p><br></p><p>Members considered that there may be an element of placebo effect with lidocaine with prilocaine use during IUD insertion and that some benefit may also result from additional lubrication from the cream. However, noting that a barrier to IUD access is fear related to insertion, the Subcommittee considered that, on balance, the availability of an evidence-based treatment to reduce pain would improve equitable access to IUDs and further support uptake. The Subcommittee <b>recommended</b> that lidocaine with prilocaine cream be funded for intra-uterine device insertion, noting that availability of appropriate pain relief, with evidence of benefit, is likely to improve the acceptability of IUDs and positively impact equitable uptake in the community setting.\xa0</p>', 'change': None}, 'Published_Application': {'s': None, 'fs': None, 'change': None}, 'PTAC_Comments': {'s': None, 'fs': None, 'change': None}, 'Outcome': {'s': None, 'fs': None, 'change': None}, 'Links': {'s': None, 'fs': None, 'change': None}, 'Formatted_Date': {'s': 'Feb 2022', 'fs': 'Feb 2022', 'change': None}, 'Event_Description': {'s': 'Clinical advice received from Reproductive and Sexual Health Subcommittee at meeting Monday 1 November 2021.', 'fs': 'Clinical advice received from Reproductive and Sexual Health Subcommittee at meeting Monday 1 November 2021.', 'change': None}, 'e': {'attributes': {'type': 'Application_Event__c', 'url': '/services/data/v65.0/sobjects/Application_Event__c/a0POZ00000PTOjq2AH'}, 'Id': 'a0POZ00000PTOjq2AH', 'Event_Date__c': '2022-02-11', 'Event_Description__c': 'Clinical advice received from Reproductive and Sexual Health Subcommittee at meeting Monday 1 November 2021.', 'Stage__c': 'Seeking Clinical Advice', 'Formatted_Date__c': 'Feb 2022', 'Published_Discussion__c': '<p>The Subcommittee noted that lidocaine with prilocaine cream is currently only funded in the community for children with a chronic medical condition requiring frequent injections or venepuncture. The Subcommittee noted that in June 2021, Pharmac consulted on declining funding applications to widen access to lidocaine with prilocaine cream in the community (to open list and for pain) following decline recommendations from PTAC.</p><p><br></p><p>The Subcommittee considered that there is currently an unmet health need for pain management during intrauterine device (IUD) insertion and that this unmet need could be somewhat met by the availability of lidocaine with prilocaine cream. </p><p><br></p><p>The Subcommittee noted the following evidence for lidocaine with prilocaine use during IUD insertion:</p><p><br></p><p class=""ql-indent-1"">A systematic review and network meta-analysis evaluating different pain lowering medications during intrauterine device insertion (<a href=""https://doi.org/10.1016/j.fertnstert.2018.11.012"" target=""_blank"">Samy et al. Fertil Steril. 2019;111</a>). </p><p class=""ql-indent-1""><br></p><p class=""ql-indent-1"">An expert opinion publication regarding the impact on pain of lidocaine in IUD insertion (<a href=""https://journals.lww.com/ebp/Citation/2021/01000/Does_topical_lidocaine_reduce_pain_more_than.31.aspx"" target=""_blank"">Lerman and Nunes. EBP. 2021;24:38-9</a>). </p><p class=""ql-indent-1""><br></p><p class=""ql-indent-1"">A randomised double-blind controlled trial of cervical lidocaine-prilocaine cream on pain perception during copper IUD insertion (<a href=""https://doi.org/10.1016/j.contraception.2016.10.011"" target=""_blank"">Abbas et al. Contracept Elsevier Inc. 2017;95:251–6</a>). </p><p><br></p><p>The Subcommittee noted the New Zealand Aotearoa’s guidance on contraception (<a href=""https://www.health.govt.nz/system/files/documents/publications/final_aotearoa_contraception_guidance.pdf"" target=""_blank"">Ministry of Health 2020</a>). This notes that the <a href=""https://www.fsrh.org/documents/ceuguidanceintrauterinecontraception/"" target=""_blank"">United Kingdom’s Faculty of Sexual and Reproductive Healthcare</a> does not recommend routinely using topical lidocaine, misoprostol, or nonsteroidal anti-inflammatory drugs to improve ease of insertion or reduce pain during the insertion of IUC. The Subcommittee also noted that New Zealand Family Planning similarly does not recommend the routine use of topical pain relief agents, with oral analgesia (paracetamol and/or ibuprofen) instead recommended to be taken prior to insertion.</p><p><br></p><p>The Subcommittee noted that currently lidocaine urethral syringes are available on Practitioners Supply Order (PSO) and can be used for cervical administration. \xa0A cervical or paracervical block is not commonly used in the community. Members noted that misoprostol may also be used, however considered that none of these treatments adequately meet the health need for pain management associated with IUD insertion in the community. </p><p><br></p><p>The Subcommittee noted that lidocaine with prilocaine should not be used routinely for IUD insertion and that likely uptake would be a significant minority of all IUD insertions. Members considered that it would most likely be used, and the most benefit gained, in situations where an individual is hesitant to receive an IUD due to fear and/or anxiety of associated pain, and those anticipated to experience difficulties during insertion. Members considered that 2 ml (one 5 g tube) of lidocaine with prilocaine cream would likely be required per procedure. </p><p><br></p><p>Members considered that there may be an element of placebo effect with lidocaine with prilocaine use during IUD insertion and that some benefit may also result from additional lubrication from the cream. However, noting that a barrier to IUD access is fear related to insertion, the Subcommittee considered that, on balance, the availability of an evidence-based treatment to reduce pain would improve equitable access to IUDs and further support uptake. The Subcommittee <b>recommended</b> that lidocaine with prilocaine cream be funded for intra-uterine device insertion, noting that availability of appropriate pain relief, with evidence of benefit, is likely to improve the acceptability of IUDs and positively impact equitable uptake in the community setting.\xa0</p>', 'Status_History__c': 'a132P000000DXEAQA4'}, 'change': None}, {'Summary': {'s': None, 'fs': None, 'change': None}, 'Published_Recommendation': {'s': None, 'fs': None, 'change': None}, 'Published_Discussion': {'s': None, 'fs': None, 'change': None}, 'Published_Application': {'s': None, 'fs': None, 'change': None}, 'PTAC_Comments': {'s': None, 'fs': None, 'change': None}, 'Outcome': {'s': None, 'fs': None, 'change': None}, 'Links': {'s': None, 'fs': None, 'change': None}, 'Formatted_Date': {'s': 'Apr 2024', 'fs': 'Apr 2024', 'change': None}, 'Event_Description': {'s': 'Clinical advice required', 'fs': 'Clinical advice required', 'change': None}, 'e': {'attributes': {'type': 'Application_Event__c', 'url': '/services/data/v65.0/sobjects/Application_Event__c/a0POZ00000PTOjs2AH'}, 'Id': 'a0POZ00000PTOjs2AH', 'Event_Date__c': '2024-04-26', 'Event_Description__c': 'Clinical advice required', 'Stage__c': 'Seeking Clinical Advice', 'Formatted_Date__c': 'Apr 2024', 'Status_History__c': 'a13OZ000009N31eYAC'}, 'change': None}, {'Summary': {'s': None, 'fs': None, 'change': None}, 'Published_Recommendation': {'s': None, 'fs': None, 'change': None}, 'Published_Discussion': {'s': None, 'fs': None, 'change': None}, 'Published_Application': {'s': None, 'fs': None, 'change': None}, 'PTAC_Comments': {'s': None, 'fs': None, 'change': None}, 'Outcome': {'s': None, 'fs': None, 'change': None}, 'Links': {'s': None, 'fs': None, 'change': None}, 'Formatted_Date': {'s': 'Feb 2025', 'fs': 'Feb 2025', 'change': None}, 'Event_Description': {'s': 'Assigned to Reproductive and Sexual Health Advisory Committee meeting to provide advice on Thursday 13 March 2025', 'fs': 'Assigned to Reproductive and Sexual Health Advisory Committee meeting to provide advice on Thursday 13 March 2025', 'change': None}, 'e': {'attributes': {'type': 'Application_Event__c', 'url': '/services/data/v65.0/sobjects/Application_Event__c/a0POZ00000PTOjt2AH'}, 'Id': 'a0POZ00000PTOjt2AH', 'Event_Date__c': '2025-02-19', 'Event_Description__c': 'Assigned to Reproductive and Sexual Health Advisory Committee meeting to provide advice on Thursday 13 March 2025', 'Stage__c': 'Seeking Clinical Advice', 'Formatted_Date__c': 'Feb 2025', 'Status_History__c': 'a13OZ00000L0vlOYAR'}, 'change': None}, {'Summary': {'s': '<p>The Reproductive and Sexual Health Advisory Committee <strong>recommended </strong>that lidocaine with prilocaine be listed with a <strong>high priority</strong>, within the context of treatments for reproductive and sexual health. This recommendation is only if lidocaine for prilocaine for IUD insertion was available on a Practitioner Supply Order (PSO).\xa0</p>', 'fs': '<p>The Reproductive and Sexual Health Advisory Committee <strong>recommended </strong>that lidocaine with prilocaine be listed with a <strong>high priority</strong>, within the context of treatments for reproductive and sexual health. This recommendation is only if lidocaine for prilocaine for IUD insertion was available on a Practitioner Supply Order (PSO).\xa0</p>', 'change': None}, 'Published_Recommendation': {'s': None, 'fs': None, 'change': None}, 'Published_Discussion': {'s': None, 'fs': None, 'change': None}, 'Published_Application': {'s': None, 'fs': None, 'change': None}, 'PTAC_Comments': {'s': None, 'fs': None, 'change': None}, 'Outcome': {'s': 'High', 'fs': 'High', 'change': None}, 'Links': {'s': '<p><a href=""https://www.pharmac.govt.nz/assets/2025-03-Reproductive-and-Sexual-Health-Advisory-Committee-Record.pdf#page=24"" target=""_blank"">Link to the relevant discussion within the meeting record.</a></p>', 'fs': '<p><a href=""https://www.pharmac.govt.nz/assets/2025-03-Reproductive-and-Sexual-Health-Advisory-Committee-Record.pdf#page=24"" target=""_blank"">Link to the relevant discussion within the meeting record.</a></p>', 'change': None}, 'Formatted_Date': {'s': 'Aug 2025', 'fs': 'Aug 2025', 'change': None}, 'Event_Description': {'s': 'Clinical advice received from Reproductive and Sexual Health Advisory Committee at meeting Thursday 13 March 2025.', 'fs': 'Clinical advice received from Reproductive and Sexual Health Advisory Committee at meeting Thursday 13 March 2025.', 'change': None}, 'e': {'attributes': {'type': 'Application_Event__c', 'url': '/services/data/v65.0/sobjects/Application_Event__c/a0POZ00000PTOju2AH'}, 'Id': 'a0POZ00000PTOju2AH', 'Event_Date__c': '2025-08-27', 'Event_Description__c': 'Clinical advice received from Reproductive and Sexual Health Advisory Committee at meeting Thursday 13 March 2025.', 'Stage__c': 'Seeking Clinical Advice', 'Links__c': '<p><a href=""https://www.pharmac.govt.nz/assets/2025-03-Reproductive-and-Sexual-Health-Advisory-Committee-Record.pdf#page=24"" target=""_blank"">Link to the relevant discussion within the meeting record.</a></p>', 'Outcome__c': 'High', 'Summary__c': '<p>The Reproductive and Sexual Health Advisory Committee <strong>recommended </strong>that lidocaine with prilocaine be listed with a <strong>high priority</strong>, within the context of treatments for reproductive and sexual health. This recommendation is only if lidocaine for prilocaine for IUD insertion was available on a Practitioner Supply Order (PSO).\xa0</p>', 'Formatted_Date__c': 'Aug 2025', 'Status_History__c': 'a13OZ00000RixcsYAB'}, 'change': None}]",Nov 2021,False,True
2,"<p>Following Clinical Advice, Pharmac staff considers the advice and the funding application under goes an assessment using our&nbsp;<a class=""external-link"" href=""https://www.pharmac.govt.nz/medicines/how-medicines-are-funded/factors-for-consideration/"" rel=""nofollow"">Factors for Consideration</a>&nbsp;framework and seeks additional information as required.</p>
<p>&nbsp;</p>
<p>Research and Economic analysis are undertaken.&nbsp; This focuses on the costs and benefits of a proposed course of action. Economics is based on three fundamental concepts that summarise the issues Pharmac faces daily:&nbsp;</p>
<ul>
<li>Scarcity &ndash; resources will always be insufficient to support all possible activities.</li>
<li>Choices &ndash; due to scarce resources, decisions must be made about how best to use them.</li>
<li>Opportunity cost &ndash; by choosing to use resources one way, we forgo other opportunities to use the same resources.</li>
</ul>
<p>&nbsp;</p>
<p>For further information on the purpose of, and techniques for, undertaking economic analysis in health care, please refer&nbsp;<a class=""external-link"" href=""https://www.pharmac.govt.nz/medicines/how-medicines-are-funded/economic-analysis/"" rel=""nofollow"">https://www.pharmac.govt.nz/medicines/how-medicines-are-funded/economic-analysis/</a></p>",2,Under Assessment,False,"[{'Summary': {'s': None, 'fs': None, 'change': None}, 'Published_Recommendation': {'s': None, 'fs': None, 'change': None}, 'Published_Discussion': {'s': None, 'fs': None, 'change': None}, 'Published_Application': {'s': None, 'fs': None, 'change': None}, 'PTAC_Comments': {'s': None, 'fs': None, 'change': None}, 'Outcome': {'s': None, 'fs': None, 'change': None}, 'Links': {'s': None, 'fs': None, 'change': None}, 'Formatted_Date': {'s': 'Feb 2022', 'fs': 'Feb 2022', 'change': None}, 'Event_Description': {'s': 'Working to compare options', 'fs': 'Working to compare options', 'change': None}, 'e': {'attributes': {'type': 'Application_Event__c', 'url': '/services/data/v65.0/sobjects/Application_Event__c/a0POZ00000PTOjr2AH'}, 'Id': 'a0POZ00000PTOjr2AH', 'Event_Date__c': '2022-02-28', 'Event_Description__c': 'Working to compare options', 'Stage__c': 'Under Assessment', 'Formatted_Date__c': 'Feb 2022', 'Status_History__c': 'a132P000000EDNqQAO'}, 'change': None}]",Feb 2022,False,True
3,"<p>Pharmac staff uses a prioritisation process to compare and rank funding options. Possible opportunities for new investment will always exceed the budget Pharmac has available; therefore, prioritisation is an intrinsic part of Pharmac’s decision-making process.</p>
<p>The relative ranking of options aims to support Pharmac&rsquo;s statutory objective &ldquo;to secure for eligible people in need of pharmaceuticals, the best health outcomes that are reasonably achievable from pharmaceutical treatment and from within the amount of funding provided&rdquo;.</p>
<p>A funding application or proposal is considered ready for prioritisation when sufficient information is available to permit it to be reviewed against Pharmac's Factors for Consideration and to inform a comparison with other possible investment decisions.</p>
<p>There is no guarantee when or if a ranked medicine will be funded.&nbsp;&nbsp;<a class=""external-link"" href=""https://www.pharmac.govt.nz/medicines/how-medicines-are-funded/prioritisation/"" rel=""nofollow"">https://www.pharmac.govt.nz/medicines/how-medicines-are-funded/prioritisation/</a></p>",3,Options Compared,False,,,False,False
4,"<p>Pharmac is consulting on a proposal to either approve or decline the application.&nbsp;We seek the views of all people who have an interest in our proposals, or who may be affected by them, to obtain feedback on our proposed approaches.</p>
<p><a class=""external-link"" href=""https://www.pharmac.govt.nz/medicines/how-medicines-are-funded/having-your-say/"" rel=""nofollow"">https://www.pharmac.govt.nz/medicines/how-medicines-are-funded/having-your-say/</a></p>",4,Under Consultation,False,,,False,False
5,"<p>Following the consultation process, Pharmac staff considers the feedback and identifies any additional information required as part of a gap analysis.&nbsp; The proposal may require further clinical advice, research, and assessment.</p>",5,Reviewing Consultation Feedback,False,,,False,False
6,"<p>We refer to our decisions about whether and how particular pharmaceuticals are publicly-funded, as &ldquo;funding decisions&rdquo;.</p>
<p>We consider and assess all funding decisions using the&nbsp;<a class=""external-link"" href=""https://www.pharmac.govt.nz/about/operating-policies-and-procedures/#factorsfc"" rel=""nofollow"">Factors for Consideration</a>. When we do so, we carefully evaluate clinical and other evidence for the benefits and suitability of a proposal, and to identify and understand the people who will be affected by it.</p>
<p>While our main task is to allocate pharmaceutical funding, we consider the benefits and costs across the whole health system now and with a long-term focus, including the effects for hospitals and primary care, and consider direct costs to patients as well as to all health sector budgets.</p>
<p>Final funding decisions are made by the Pharmac Board or delegated to senior Pharmac staff as required by the Board.</p>
<p>&nbsp;</p>",6,Decision,True,,,False,False
